Management of refractory autoimmune hemolytic anemia via allogeneic stem cell transplantation

Bone Marrow Transplant. 2016 Nov;51(11):1504-1506. doi: 10.1038/bmt.2016.152. Epub 2016 Jun 6.

Authors

L Rotenstein¹, A Nathan², I Ghobrial³, J Antin³, A Parnes⁴

Affiliations

¹ Harvard Medical School, Boston, MA, USA.
² Department of Internal Medicine, Brigham and Women's Hospital, Boston, MA, USA.
³ Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
⁴ Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.

PMID: 27272445
DOI: 10.1038/bmt.2016.152

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Anemia, Hemolytic, Autoimmune / etiology
Anemia, Hemolytic, Autoimmune / therapy*
Disease Management
Hematopoietic Stem Cell Transplantation / methods*
Humans
Immunosuppressive Agents / therapeutic use
Lymphoproliferative Disorders
Middle Aged
Salvage Therapy / methods*
Sirolimus / therapeutic use
Tacrolimus / therapeutic use
Transplantation, Homologous
Waldenstrom Macroglobulinemia / complications
Waldenstrom Macroglobulinemia / pathology
Waldenstrom Macroglobulinemia / therapy*

Substances

Immunosuppressive Agents
Sirolimus
Tacrolimus